|
RS53350B
(sr)
|
2008-09-22 |
2014-10-31 |
Array Biopharma, Inc. |
Supstituisana jedinjenja imidazo[1,2-b]piridazina kao inhibitori trk kinaze
|
|
EA038195B1
(ru)
|
2009-01-16 |
2021-07-22 |
Экселиксис, Инк. |
Малатная соль n-(4-{[6,7-бис-(метилокси)хинолин-4-ил]окси}фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида и ее применение для лечения рака почек и печени
|
|
AR077468A1
(es)
|
2009-07-09 |
2011-08-31 |
Array Biopharma Inc |
Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
|
|
UA108618C2
(uk)
|
2009-08-07 |
2015-05-25 |
|
Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
|
|
KR102015402B1
(ko)
|
2010-05-20 |
2019-08-28 |
어레이 바이오파마 인크. |
Trk 키나제 저해제로서의 매크로시클릭 화합물
|
|
DK2621481T4
(da)
|
2010-09-27 |
2023-01-09 |
Exelixis Inc |
Dobbelte inhibitorer af MET og VEGF til behandling af kastrationsresistent prostatacancer og osteoblastiske knoglemetastaser
|
|
TWI640509B
(zh)
|
2011-02-10 |
2018-11-11 |
艾克塞里克斯公司 |
製造喹啉化合物之方法及包含該化合物之醫藥組合物
|
|
GEP201606523B
(en)
|
2011-09-22 |
2016-08-10 |
Exelixis Inc |
Method for treating osteoporosis
|
|
EP2768796B1
(en)
|
2011-10-20 |
2019-11-20 |
Exelixis, Inc. |
Process for preparing quinoline derivatives
|
|
WO2013166296A1
(en)
|
2012-05-02 |
2013-11-07 |
Exelixis, Inc. |
A dual met - vegf modulator for treating osteolytic bone metastases
|
|
EP2892532B1
(en)
*
|
2012-09-07 |
2019-02-13 |
Exelixis, Inc. |
Inhibitors of met, vegfr and ret for use in the treatment of lung adenocarcinoma
|
|
CA2907334C
(en)
*
|
2013-03-15 |
2021-12-07 |
Exelixis, Inc. |
Metabolites of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
|
|
US11564915B2
(en)
|
2013-04-04 |
2023-01-31 |
Exelixis, Inc. |
Cabozantinib dosage form and use in the treatment of cancer
|
|
AU2015218236B2
(en)
|
2014-02-14 |
2019-06-13 |
Exelixis, Inc. |
Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use
|
|
US10159666B2
(en)
|
2014-03-17 |
2018-12-25 |
Exelixis, Inc. |
Dosing of cabozantinib formulations
|
|
EP3132054B1
(en)
*
|
2014-04-18 |
2021-06-30 |
Blueprint Medicines Corporation |
Met fusions
|
|
EP3906921A1
(en)
*
|
2014-04-25 |
2021-11-10 |
Exelixis, Inc. |
Method of treating lung adenocarcinoma
|
|
CN104788372B
(zh)
*
|
2014-07-25 |
2018-01-30 |
上海圣考医药科技有限公司 |
一种氘代卡博替尼衍生物、其制备方法、应用及其中间体
|
|
CN106715397B
(zh)
|
2014-07-31 |
2021-07-23 |
埃克塞里艾克西斯公司 |
制备氟-18标记的卡博替尼及其类似物的方法
|
|
BR112017002318A2
(pt)
|
2014-08-05 |
2018-07-17 |
Exelixis, Inc. |
combinações de fármacos para tratar mieloma múltiplo.
|
|
JP6914834B2
(ja)
|
2014-11-16 |
2021-08-04 |
アレイ バイオファーマ インコーポレイテッド |
（Ｓ）−Ｎ−（５−（（Ｒ）−２−（２，５−ジフルオロフェニル）−ピロリジン−１−イル）−ピラゾロ［１，５−ａ］ピリミジン−３−イル）−３−ヒドロキシピロリジン−１−カルボキサミド硫酸水素塩の結晶形
|
|
WO2016127074A1
(en)
|
2015-02-06 |
2016-08-11 |
Blueprint Medicines Corporation |
2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors
|
|
HUE053067T2
(hu)
|
2015-07-16 |
2021-06-28 |
Array Biopharma Inc |
Helyettesített pirazolo[1,5-A]piridin vegyületek, mint RET kináz inhibitorok
|
|
TN2018000138A1
(en)
|
2015-10-26 |
2019-10-04 |
Array Biopharma Inc |
Point mutations in trk inhibitor-resistant cancer and methods relating to the same
|
|
NZ742351A
(en)
|
2015-11-02 |
2023-03-31 |
Blueprint Medicines Corp |
Inhibitors of ret
|
|
UY37155A
(es)
|
2016-03-17 |
2017-10-31 |
Blueprint Medicines Corp |
Inhibidores de ret
|
|
AU2017246554B2
(en)
|
2016-04-04 |
2022-08-18 |
Loxo Oncology, Inc. |
Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
|
|
ES2987501T3
(es)
|
2016-04-04 |
2024-11-15 |
Loxo Oncology Inc |
Métodos de tratamiento de cánceres pediátricos
|
|
US10045991B2
(en)
|
2016-04-04 |
2018-08-14 |
Loxo Oncology, Inc. |
Methods of treating pediatric cancers
|
|
CN109069499A
(zh)
|
2016-04-15 |
2018-12-21 |
埃克塞里艾克西斯公司 |
使用 n-(4-(6,7-二甲氧基喹啉-4-基氧基)苯基)-n’-(4-氟苯基)环丙烷-1,1-二甲酰胺,(2s)-羟基丁二酸盐治疗肾细胞癌的方法
|
|
AU2017263174A1
(en)
|
2016-05-13 |
2018-12-13 |
Instituto de Medicina Molecular João Lobo Antunes |
Methods of treating diseases associated with ILC3 cells
|
|
KR102566858B1
(ko)
|
2016-05-18 |
2023-08-11 |
어레이 바이오파마 인크. |
(s)-n-(5-((r)-2-(2,5-디플루오로페닐)피롤리딘-1-일)-피라졸로[1,5-a]피리미딘-3-일)-3-히드록시피롤리딘-1-카르복사미드의 제조 방법
|
|
WO2018017983A1
(en)
|
2016-07-22 |
2018-01-25 |
Blueprint Medicines Corporation |
Compounds useful for treating disorders related to ret
|
|
US10035789B2
(en)
|
2016-07-27 |
2018-07-31 |
Blueprint Medicines Corporation |
Compounds useful for treating disorders related to RET
|
|
TWI752098B
(zh)
|
2016-10-10 |
2022-01-11 |
美商亞雷生物製藥股份有限公司 |
作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
|
|
TWI704148B
(zh)
|
2016-10-10 |
2020-09-11 |
美商亞雷生物製藥股份有限公司 |
作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
|
|
JOP20190092A1
(ar)
|
2016-10-26 |
2019-04-25 |
Array Biopharma Inc |
عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
|
|
US11168090B2
(en)
|
2017-01-18 |
2021-11-09 |
Array Biopharma Inc. |
Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors
|
|
WO2018136663A1
(en)
|
2017-01-18 |
2018-07-26 |
Array Biopharma, Inc. |
Ret inhibitors
|
|
JOP20190213A1
(ar)
|
2017-03-16 |
2019-09-16 |
Array Biopharma Inc |
مركبات حلقية ضخمة كمثبطات لكيناز ros1
|
|
SG11202001212SA
(en)
|
2017-08-21 |
2020-03-30 |
Taiho Pharmaceutical Co Ltd |
Fusion protein of dctn1 protein with ret protein
|
|
TWI812649B
(zh)
|
2017-10-10 |
2023-08-21 |
美商絡速藥業公司 |
6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
|
|
TWI791053B
(zh)
|
2017-10-10 |
2023-02-01 |
美商亞雷生物製藥股份有限公司 |
6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
|
|
EP3740490A1
(en)
|
2018-01-18 |
2020-11-25 |
Array Biopharma, Inc. |
Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
|
|
EP3740491A1
(en)
|
2018-01-18 |
2020-11-25 |
Array Biopharma, Inc. |
Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
|
|
CA3087972C
(en)
|
2018-01-18 |
2023-01-10 |
Array Biopharma Inc. |
Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
|
|
GEAP202415420A
(en)
|
2018-01-26 |
2024-12-25 |
Exelixis Inc |
Compounds for the treatment of kinase-dependent disorders
|
|
EP3773589B1
(en)
|
2018-04-03 |
2023-11-01 |
Blueprint Medicines Corporation |
Ret inhibitor for use in treating cancer having a ret alteration
|
|
CN120305263A
(zh)
|
2018-06-15 |
2025-07-15 |
汉达癌症医药责任有限公司 |
卡博替尼的盐类于制备治疗癌症的剂型的用途
|
|
CN110862397A
(zh)
*
|
2018-08-27 |
2020-03-06 |
北京赛特明强医药科技有限公司 |
二噁烷并喹唑啉与二噁烷并喹啉类化合物及其制备方法与应用
|
|
JP2022500383A
(ja)
|
2018-09-10 |
2022-01-04 |
アレイ バイオファーマ インコーポレイテッド |
Ｒｅｔキナーゼ阻害剤としての縮合複素環式化合物
|
|
CA3183728A1
(en)
|
2020-05-29 |
2021-12-02 |
Blueprint Medicines Corporation |
Solid forms of pralsetinib
|
|
DE102020005002A1
(de)
*
|
2020-08-17 |
2022-02-17 |
Epo Experimentelle Pharmakologie & Onkologie Berlin-Buch Gmbh |
Mittel zur Therapie von Tumorerkrankungen
|
|
JP2024522938A
(ja)
|
2021-06-03 |
2024-06-21 |
フンダサン デー．アンナ ジ ソーメル チャンパリマウド エー ドクトル カルロス モンテス チャンパリマウド |
脳－脂肪回路を介してｉｌｃ２および肥満度を制御する神経－間葉単位
|
|
CN114354789B
(zh)
*
|
2021-12-27 |
2023-08-29 |
深圳海王医药科技研究院有限公司 |
一种同时测定卡博替尼类似物及其有关物质的方法
|
|
WO2023230770A1
(en)
*
|
2022-05-30 |
2023-12-07 |
Suzhou Singleron Biotechnologies Co., Ltd. |
Methods of lung adenocarcinoma treatment with non anti-luad drugs or compounds
|
|
AU2024215796A1
(en)
|
2023-01-31 |
2025-05-15 |
Handa Oncology, Llc |
Improved cabozantinib compositions and methods of use
|